Detalhe da pesquisa
1.
Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma-like carcinoma.
Clin Transl Immunology;
13(6): e1515, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38835955
2.
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.
JAMA Oncol;
2024 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38869865
3.
Mixed response to the first-line treatment of KRAS G12C inhibitor, sotorasib, in non-small cell lung cancer: A brief report.
Clin Case Rep;
12(6): e8866, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38799516
4.
Genotyping of RB1 status identifies two distinct subtypes in EGFR-mutant lung cancers with SCLC transformation.
Clin Transl Med;
14(5): e1683, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38736106
5.
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
Br J Cancer;
130(10): 1679-1686, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38575731
6.
Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.
J Transl Med;
22(1): 326, 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38566102
7.
Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma.
Oncoimmunology;
13(1): 2340154, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38601319
8.
Molecular features and clinical outcomes of EGFR-mutated, MET-amplified non-small-cell lung cancer after resistance to dual-targeted therapy.
Ther Adv Med Oncol;
16: 17588359241234504, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38449561
9.
Plasma ddPCR for the detection of MET amplification in advanced NSCLC patients: a comparative real-world study.
Ther Adv Med Oncol;
16: 17588359241229435, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38333112
10.
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.
Sci Bull (Beijing);
69(4): 535-543, 2024 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38185589
11.
Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes.
J Thorac Oncol;
19(4): 601-612, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37981218
12.
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study.
Signal Transduct Target Ther;
8(1): 442, 2023 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38057314
13.
Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer.
J Thorac Dis;
15(9): 4620-4635, 2023 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37868836
14.
Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial.
EClinicalMedicine;
64: 102238, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37781161
15.
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients.
Cancer Cell;
41(10): 1763-1773.e4, 2023 10 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37816331
16.
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.
Nat Med;
29(8): 2079-2086, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37488286
17.
Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patients.
Ther Adv Med Oncol;
15: 17588359231167818, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37113733
18.
Pathological characteristics and tumour immune microenvironment of lung malignancies with RET rearrangement.
Cancer Treat Res Commun;
35: 100707, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37121144
19.
Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.
Mol Oncol;
17(8): 1581-1594, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078460
20.
Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer.
Lung Cancer;
178: 66-74, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36806896